Free Trial
NASDAQ:TCRT

Alaunos Therapeutics Q2 2023 Earnings Report

Alaunos Therapeutics logo
$2.63 -0.05 (-1.87%)
Closing price 04/25/2025 03:57 PM Eastern
Extended Trading
$2.52 -0.12 (-4.37%)
As of 04/25/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alaunos Therapeutics EPS Results

Actual EPS
-$6.00
Consensus EPS
-$6.00
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Alaunos Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alaunos Therapeutics Announcement Details

Quarter
Q2 2023
Time
Q2 2023 Earnings Release
Conference Call Date
Monday, August 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Alaunos Therapeutics' Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Alaunos Therapeutics Earnings Headlines

Trump’s Secret Social Security Plan?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
See More Alaunos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email.

About Alaunos Therapeutics

Alaunos Therapeutics (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

View Alaunos Therapeutics Profile

More Earnings Resources from MarketBeat